Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Orelabrutinib plus rituximab-based chemoimmunotherapy regimens in relapsed or refractory marginal zone lymphoma: A multicentric phase II trial

Shaohua Wu, Li Ma, Jingrong Wang et al. Nov 03, 2025 pp. 7117-7117 10.1182/blood-2025-7117

Abstract Background:Marginal zone lymphoma (MZL) is a heterogeneous B-cell malignancy that is often managed with chemoimmunotherapy (CIT) in...

Real-world outcomes and disparities of ph+ ALL in a Latino population

Christian Gonzales-Gavancho, Hafid De Ruben Calderon Huaycochea, Gabriel De la Cruz Ku et al. Nov 03, 2025 pp. 6843-6843 10.1182/blood-2025-6843

Abstract Introduction: Despite recent treatment advances in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL), survival...

Clinical efficacy and safety for pediatric patients with severe combined immunodeficiency disease treated with modified allo-haploidentical stem cell transplantation

Yan Yue, Hebing Zhou, Juan Zhang et al. Nov 03, 2025 pp. 7762-7762 10.1182/blood-2025-7762

Abstract Purpose: Hematopoietic stem cell transplantation (HSCT) is the curative treatment for severe combined immunodeficiency disease (SCI...

The myeloid transcription factor cebpa functions as a sequence-specific RNA binding protein via a novel n-terminal domain essential for macrophage differentiation

Mahmoud Bassal, Yanzhou Zhang, Yanjing Liu et al. Nov 03, 2025 pp. 188-188 10.1182/blood-2025-188

Abstract Introduction: CCAAT/Enhancer Binding Protein Alpha (CEBPa) is a master regulator indispensable for neutrophil development, yet its...

Enhanced tyrosine kinase inhibitor response on chronic myeloid leukemia cells upon MS4A3 mRNA delivery

Cansu Tunc, Anthony Pomicter, Nataly Cruz-Rodriguez et al. Nov 03, 2025 pp. 2544-2544 10.1182/blood-2025-2544

Abstract Chronic myeloid leukemia (CML) is caused by BCR::ABL1, a constitutively active tyrosine kinase that induces profound expansion of t...

Exploration of optimal high-dose methotrexate-based therapy for patients with primary CNS lymphoma: A real-world study in China

Huiying Zhu, Zhangyuting He, Chong Wei et al. Nov 03, 2025 pp. 3693-3693 10.1182/blood-2025-3693

Abstract Introduction: Primary CNS lymphoma (PCNSL) is a rare and highly aggressive extranodal non-Hodgkin lymphoma, with a dismal outcome in...

Emicizumab levels in patients with acquired and congenital Hemophilia A

Christiane Dobbelstein, Ivonne Wieland, Andreas Tiede et al. Nov 03, 2025 pp. 1312-1312 10.1182/blood-2025-1312

Abstract Introduction Emicizumab is a bispecific antibody that mimics the action of FVIII and has emerged as an effectiv...

Testing for hereditary α-tryptasemia (HαT) / TPSAB1 copy number analysis by droplet digital PCR: Genotypes and phenotypes one year after TPSAB1 assay go-live

Malia Deshotel, Peng Li, Margaret Williams et al. Nov 03, 2025 pp. 1222-1222 10.1182/blood-2025-1222

Abstract Hereditary α-tryptasemia (HαT) is an autosomal dominant genetic trait discovered in 2016 that affects 4-6% of the Western populatio...

The small activating RNA AW1-51 induces locus-specific demethylation and CEBPA protein early upregulation

Juan Rodrigo Patiño-Mercau, Giulia Gaggi, Marta Borchiellini et al. Nov 03, 2025 pp. 6791-6791 10.1182/blood-2025-6791

Abstract Aberrant DNA methylation is a well-known feature of hematological malignancies, frequently leading to tumor suppressor genes silenc...

Platelets enhance factor VIII activity through protection from activated Protein C

Valerie Novakovic, Jialan Shi, Lindsey George et al. Nov 03, 2025 pp. 3060-3060 10.1182/blood-2025-3060

Abstract Introduction Phospholipid membranes provide a catalytic surface for factor VIII (FVIII) activity in the blood c...

Hematologist based management of ocular adverse events using the VRA tool in newly-diagnosed myeloma patients, ineligible for ASCT who received belantamab mafodotin plus lenalidomide/dexamethasone: Updated results from the randomized part 2 of bela-rd Study

Evangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos et al. Nov 03, 2025 pp. 4038-4038 10.1182/blood-2025-4038

Abstract Introduction Belantamab mafodotin (belamaf) combinations showed superior efficacy over standard regimens in relapsed/refractory mult...

Ruxolitinib combined with dexamethasone is a promising prophylaxis method for differentiation syndrome in acute promyelocytic leukemia (APL2022)

Hongming Zhu, Yubing Zhao, Xiaojing Lin et al. Nov 03, 2025 pp. 5214-5214 10.1182/blood-2025-5214

Abstract Introduction: Acute promyelocytic leukemia (APL) has been highly cured with all-trans retinoic acid (ATRA) and...

Fibrin clot shields drive clonal selection of cancer cells: Procoagulant properties and proliferative survival of clot embedded cancer cells. a novel model of tumor microenvironment remodeling

Noelin Baskaran, Mohammed Baghdadi, Pedro Henrique Las Casas et al. Nov 03, 2025 pp. 1316-1316 10.1182/blood-2025-1316

Abstract Introduction: Cancer cells (CaCe) expressing Tissue Factor (TF) initiate thrombin generation and fibrin formation, contributing to...

Projecting non Hodgkin lymphoma mortality for young adults in the United States(2024-2040):a national population-based modeling study

Abdullah Ahmad, Fiqe Khan, Zeeshan Majeed et al. Nov 03, 2025 pp. 8073-8073 10.1182/blood-2025-8073

Abstract Background: Non-Hodgkin lymphoma (NHL) represents a significant cancer burden in young adults. While survival rates have improved i...

Cardio-safe degrader CT-03p degrades MCL-1 and overcomes venetoclax resistance in AML.

Po Yee Mak, Abhishek Maiti, Tomasz Tomczyk et al. Nov 03, 2025 pp. 3266-3266 10.1182/blood-2025-3266

Abstract BCL-2 family proteins are key cell death regulators. Among them, BCL-2 and MCL-1 are major anti-apoptotic proteins and play critica...

Setting the stage in KMT2A rearranged acute myelogenous leukemia in the era of menin inhibitors

Omar Alzarkali, Zena Komrokji, Najla Al Ali et al. Nov 03, 2025 pp. 3393-3393 10.1182/blood-2025-3393

Abstract Introduction: Lysine methyltransferase 2A gene rearrangements (KMT2Ar) typically occur via several translocations involving the 11q2...

A randomized phase II study of daratumumab, lenalidomide, ixazomib, and dexamethasone in transplant-ineligible or deferred patients with newly diagnosed multiple myeloma: Alliance Foundation Trial 41 (AFT-41)

Andrew Yee, Elizabeth O'Donnell, Omar Nadeem et al. Nov 03, 2025 pp. 4053-4053 10.1182/blood-2025-4053

Abstract Introduction The treatment of newly diagnosed multiple myeloma (NDMM) has rapidly evolved. Quadruplet induction combining an anti-CD...

Pulmonary complications in acute myelogenous leukemia in post allogenic hematopoietic stem cell transplant period and yield of bronchoalveolar lavage and biopsy- single center experience

Aneela Majeed, Eric Cober, Simon Mucha et al. Nov 03, 2025 pp. 3381-3381 10.1182/blood-2025-3381

Abstract Background Pulmonary complications occur in 40-80% of acute myeloid leukemia (AML) and hemopoietic stem cell transplant (HSCT) patie...

Targeting of tumor antigen CD38 and stress antigens MICA/B by CAR T cells provides a unique approach for the comprehensive treatment of multiple myeloma

Soheila Shirinbak, Shilpi Chandra, Brian Groff et al. Nov 03, 2025 pp. 2350-2350 10.1182/blood-2025-2350

Abstract Introduction: Recently approved autologous chimeric antigen receptor (CAR) T-cell therapies (Abecma® and Carvykti®) have demonstrat...

Impact of early bacteremia on clinical outcomes following allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide-based gvhd prophylaxis

Moazzam Shahzad, Shah Rukh, Aroog Khaliq et al. Nov 03, 2025 pp. 4200-4200 10.1182/blood-2025-4200

Abstract Background Bloodstream infections (BSIs) remain a significant cause of morbidity and mortality following allogeneic hematopoietic c...

Hemoglobin SC disease: Clinical analysis from the Georgia comprehensive sickle cell center at grady memorial hospital, Atlanta, Georgia.

Abraham Attah, Abisola Ajayi, Jhonsley Frederic et al. Nov 03, 2025 pp. 6533-6533 10.1182/blood-2025-6533

Abstract Background: Hemoglobin (Hb) SC disease is a compound sickle cell variant that affects about 25% of patients with sickle cell diseas...

Impact of immunoglobulin supplementation on infection rates in myeloma patients receiving novel immunotherapies

Efstathios Kastritis, Eirini Solia, Ilias Katsadouros et al. Nov 03, 2025 pp. 3999-3999 10.1182/blood-2025-3999

Abstract Infections remain a major challenge in the management of patients with multiple myeloma (MM), associated with significant morbidity...

Trends and disparities in mortality from chronic lymphocytic leukemia in the geriatric population in the United States from 1999 to 2020: A nationwide analysis

Muhammad Shaheer Mannan, Allahdad Khan, Arfa Ahmad et al. Nov 03, 2025 pp. 8016-8016 10.1182/blood-2025-8016

Abstract Background: Chronic Lymphocytic Leukemia (CLL) is the most prevalent leukemia among adults in Western populations, disproportionate...

Impact of MDS-associated mutations and age on outcomes in NPM1-mutated AML

Vivian Liu, Megan Othus, Rhonda Ries et al. Nov 03, 2025 pp. 6999-6999 10.1182/blood-2025-6999

Abstract The current European Leukemia Net guidelines (ELN22) classify AML patients with intermediate-risk cytogenetics and MDS-associated m...

Nivolumab and pembrolizumab in treatment of relapsed or refractory classical Hodgkin lymphoma: Systematic review and meta-analysis of clinical trials

Artem Oganesyan, Andrew Gregory, Mark Gregory et al. Nov 03, 2025 pp. 5400-5400 10.1182/blood-2025-5400

Abstract Introduction: Relapsed or refractory (r/r) disease is seen in 20-30% patients with classic Hodgkin lymphoma (cHL), where 10-15% of...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page